GlassScriptPhysician profile
Jazmine Quintero
NPI 1578171211
$5,713.32
in general payments reported to CMS, 2019-2025
20 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $526 · 2024: $2,455 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,713.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $664.64 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $623.47 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $612.76 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $584.12 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $565.35 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbvie INC. | $482.33 | 2024-2025 | |
| Lundbeck LLC | $415.87 | 2024-2025 | Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $395.76 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $379.43 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $320.65 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $114.28 | 2024 | Quviviq |
| Phadia US INC. | $111.11 | 2024 | Immunocap |
| Almatica Pharma LLC | $104.67 | 2024-2025 | Loreev Xr |
| Harmony Biosciences LLC | $89.17 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.76 | 2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $48.34 | 2025 | Erzofri Extended-Release |
| Janssen Pharmaceuticals, INC | $42.32 | 2024 | Invega Sustenna |
| Indivior INC. | $34.15 | 2024 | Perseris |
| Xeris Pharmaceuticals, INC. | $21.62 | 2025 | Keveyis |
| Tris Pharma INC | $21.52 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jazmine Quintero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.